Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

BRAFV600E mutation testing in fine needle aspirates of thyroid nodules: potential value of real-time PCR.

Kwak JY, Han KH, Yoon JH, Kim EK, Moon HJ, Kim YL, Park SJ, Choi JR.

Ann Clin Lab Sci. 2012 Summer;42(3):258-65.

PMID:
22964613
2.

Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area.

Kwak JY, Kim EK, Kim JK, Han JH, Hong SW, Park TS, Choi JR.

Head Neck. 2010 Apr;32(4):490-8. doi: 10.1002/hed.21210.

PMID:
19672964
3.

Pyrosequencing cut-off value identifying BRAFV600E mutation in fine needle aspiration samples of thyroid nodules.

Yeo MK, Liang ZL, Oh T, Moon Y, An S, Kim MK, Kim KS, Shong M, Kim JM, Jo YS.

Clin Endocrinol (Oxf). 2011 Oct;75(4):555-60. doi: 10.1111/j.1365-2265.2011.04115.x.

PMID:
21609347
4.

Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules.

Koh J, Choi JR, Han KH, Kim EK, Yoon JH, Moon HJ, Kwak JY.

PLoS One. 2013 May 24;8(5):e64505. doi: 10.1371/journal.pone.0064505.

5.

Allele-specific PCR with competitive probe blocking for sensitive and specific detection of BRAF V600E in thyroid fine-needle aspiration specimens.

Smith GD, Zhou L, Rowe LR, Jarboe EA, Collins BT, Bentz JS, Wittwer CT, Chadwick BE.

Acta Cytol. 2011;55(6):576-83. doi: 10.1159/000333453.

PMID:
22156469
6.
7.

BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.

Nam SY, Han BK, Ko EY, Kang SS, Hahn SY, Hwang JY, Nam MY, Kim JW, Chung JH, Oh YL, Shin JH.

Thyroid. 2010 Mar;20(3):273-9. doi: 10.1089/thy.2009.0226.

PMID:
20187782
8.

[Clinical role of BRAF V600E mutation testing in thyroid nodules].

Wan H, Zhang B, Wang Y, Xiao T, Guo H, Liu W, Yan D, Xu Z, Tang P.

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014 Jun;49(6):468-72. Chinese.

PMID:
25241863
9.
10.

Incidence and predictive factors of inadequate fine-needle aspirates for BRAF(V600E) mutation analysis in thyroid nodules.

Lee KH, Kim HS, Han BK, Ko EY, Ki CS, Shin JH.

AJR Am J Roentgenol. 2014 Feb;202(2):391-6. doi: 10.2214/AJR.12.10291.

PMID:
24450682
11.

Initial clinical experience with BRAF(V600E) mutation analysis of core-needle biopsy specimens from thyroid nodules.

Choi SH, Baek JH, Lee JH, Choi YJ, Ha EJ, Song DE, Kim JK, Chung KW, Kim TY, Kim WB, Shong YK.

Clin Endocrinol (Oxf). 2016 Apr;84(4):607-13. doi: 10.1111/cen.12866.

PMID:
26215382
12.

BRAF(V600E) assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay.

Guerra A, Di Stasi V, Zeppa P, Faggiano A, Marotta V, Vitale M.

Endocrine. 2014 Mar;45(2):249-55. doi: 10.1007/s12020-013-9994-y.

PMID:
23775008
13.

Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule.

Kang G, Cho EY, Shin JH, Chung JH, Kim JW, Oh YL.

Cancer Cytopathol. 2012 Feb 25;120(1):44-51. doi: 10.1002/cncy.20179.

14.

Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration.

Moon HJ, Kim EK, Chung WY, Choi JR, Yoon JH, Kwak JY.

Ann Surg Oncol. 2011 Mar;18(3):792-9. doi: 10.1245/s10434-010-1354-z.

PMID:
20945104
15.

Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.

Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park DJ, Lee HS, Cho BY, Lee ES, Kim SW.

Clin Endocrinol (Oxf). 2006 Nov;65(5):660-6.

PMID:
17054470
16.

Diagnostic value of B-RAF(V600E) in difficult-to-diagnose thyroid nodules using fine-needle aspiration: systematic review and meta-analysis.

Jia Y, Yu Y, Li X, Wei S, Zheng X, Yang X, Zhao J, Xia T, Gao M.

Diagn Cytopathol. 2014 Jan;42(1):94-101. doi: 10.1002/dc.23044. Review.

PMID:
24167125
17.

Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.

Kwon HJ, Kim EK, Kwak JY.

Pathol Res Pract. 2015 Sep;211(9):671-6. doi: 10.1016/j.prp.2015.06.010.

PMID:
26187369
18.

mRNA BRAF expression helps to identify papillary thyroid carcinomas in thyroid nodules independently of the presence of BRAFV600E mutation.

Araujo PP, Marcello MA, Tincani AJ, Guilhen AC, Morari EC, Ward LS.

Pathol Res Pract. 2012 Aug 15;208(8):489-92. doi: 10.1016/j.prp.2012.05.013.

PMID:
22770943
19.

The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules.

Lee EJ, Song KH, Kim DL, Jang YM, Hwang TS, Kim SK.

Clin Endocrinol (Oxf). 2011 Dec;75(6):844-50. doi: 10.1111/j.1365-2265.2011.04154.x.

PMID:
21707687
20.

BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population.

Kim SW, Lee JI, Kim JW, Ki CS, Oh YL, Choi YL, Shin JH, Kim HK, Jang HW, Chung JH.

J Clin Endocrinol Metab. 2010 Aug;95(8):3693-700. doi: 10.1210/jc.2009-2795.

PMID:
20501689
Items per page

Supplemental Content

Support Center